Crescent Biopharma, Inc.

12.50+0.00 (+0%)

Oct 29, 4:00:01 PM EDT · NasdaqCM · CBIO · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

209.78M

P/E (TTM)

Basic EPS (TTM)

Dividend Yield

Recent Filings

8-K

7/31/25Jul 31, 2025

10-Q

7/31/25Jul 31, 2025

8-K

6/18/25Jun 18, 2025

8-K

6/6/25Jun 6, 2025

8-K

5/30/25May 30, 2025

About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts.

CEO

Mr. Joshua T. Brumm

IPO

1/10/2014

Website

https://crescentbiopharma.com

Employees

Sector

Healthcare

Industry

Biotechnology